NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today the CE marking of Eve™, a critical congenital heart disease (CCHD) newborn screening application, for the Rad-97™ Pulse ...
Quantabio, a leading provider of robust DNA and RNA amplification reagents for the most demanding molecular testing and life science research applications, today announced the launch of the sparQ™ ...
For women who are vaccinated against HPV by age 30 years, a high-value screening program likely involves less frequent screening.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results